Addressing Unmet Needs in Refractory Crohn's Disease and Exploring Novel Therapeutic Approaches

Crohn's disease is a chronic inflammatory bowel disease, and a significant number of patients experience refractory symptoms that do not respond to existing anti-TNFα agents or other biological therapies like integrin inhibitors. To address this, the Icahn School of Medicine at Mount Sinai is evaluating a groundbreaking treatment approach in a Phase 2 clinical trial (MASCT-CD) involving autologous hematopoietic stem cell transplantation (HSCT) to completely reconstruct the damaged immune system. This represents a paradigm shift, moving beyond mere symptom management to reset the immune system and fundamentally control the disease.

Synergistic Strategy: Combining Autologous HSCT with Vedolizumab

While autologous HSCT has demonstrated high remission rates, it has limitations due to disease relapse over time. This trial employs a sophisticated strategy by administering vedolizumab (Entyvio), a Takeda Pharmaceuticals' alpha4beta7 integrin-targeting monoclonal antibody, as maintenance therapy after transplantation, coinciding with the immune system's reconstitution. This aims to prevent relapse by leveraging Entyvio's selective action on the gut, minimizing systemic side effects while maximizing the long-term efficacy of the transplant.

Detailed Clinical Trial Design and Rigorous Monitoring

The Phase 2 clinical trial (NCT03219359) is a single-group, open-label study involving a total of 50 patients. Patients undergo mobilization and collection procedures, followed by high-dose chemotherapy and autologous HSCT. Subsequently, they receive a total of 8 infusions of vedolizumab. At the 6-month post-transplant mark, remission status will be rigorously assessed through endoscopic and imaging examinations to objectively demonstrate the safety and long-term efficacy of the treatment.

Patent Expiry of Blockbuster Entyvio and Market Defense Strategy

Entyvio is a key growth driver for Takeda Pharmaceuticals, generating 958 billion yen (approximately $6 billion to $7 billion) in revenue in fiscal year 2025. However, with patent expiry (Loss of Exclusivity, LOE) looming between 2028 and 2032, defending against biosimilar entry is a critical priority. This investigator-initiated trial (IIT) aims to gather academic evidence for expanding the indications to include ultra-refractory patients who have failed existing treatments, which could extend Entyvio's prescription lifespan and maintain its market dominance.

Competitive Landscape and Long-Term Outlook for Refractory Treatment Market

The global Crohn's disease treatment market is estimated at $11.9 billion to $14.4 billion by 2026, with AbbVie's Skyrizi and Johnson & Johnson's Stelara being key competitors. While the autologous HSCT combination therapy, which involves high-risk chemotherapy, is unlikely to directly replace first-line treatments, it can offer a last-resort treatment option for severe patients who are unresponsive to all biological therapies. If this trial is successful, it is expected to overcome the limitations of existing standard treatments and establish a dominant position in the ultra-refractory disease market.